Page 1

Quidel Contact : Quidel Corporation Randy Steward Chief Financial Officer 858.552.7931 QUIDEL Media and Investors Contact : Quidel Corporation Ruben Argueta 858.646.8023 rargueta@quidel.com QUIDEL REPORTS THIRD QUARTER 2021 FINANCIAL RESULTS SAN DIEGO , CA – November 4 , 2021 — Quidel Corporation ( NASDAQ : QDEL ) , a provider of rapid diagnostic testing solutions , cellular - based virology assays and molecular diagnostic systems , announced today financial results for the third quarter ended September 30 , 2021 . Third Quarter 2021 Highlights • Total revenues increased 7 % to $ 509.7 million , from $ 476.1 million in the third quarter of 2020 . Total sales of COVID - 19 products increased 7 % to $ 402.6 million , from $ 375.7 million in the third quarter of 2020 . • • • • • Total sales of Influenza products were $ 13.8 million , compared to $ 9.0 million in the third quarter of 2020 . Reported GAAP EPS of $ 5.08 per diluted share in the third quarter of 2021 , as compared to $ 5.33 per diluted share in the third quarter of 2020 . Reported non - GAAP EPS of $ 5.36 per diluted share in the third quarter of 2021 , as compared to $ 5.78 per diluted share in the third quarter of 2020 . Resolved ongoing litigation with Beckman Coulter ; substantially completed transition of the BNP business to Beckman Coulter for cash payments to Quidel of between $ 70.0 million and $ 75.0 million per year from 2022 through 2029 , and pro - rated for 2021 . Received the CE Mark for Savanna® multiplex molecular analyzer and Savanna RVP4 assay . Made QuickVue® At - Home OTC COVID - 19 Test available to consumers at CVS Pharmacy and online at cvs.com . Secured 12 - month agreement with U.S. government worth over $ 500 million to supply QuickVue At - Home OTC COVID - 19 Tests . Results for the Third Quarter 2021 Total revenues for the third quarter of 2021 were $ 509.7 million , versus $ 476.1 million for the third quarter of 2020. The 7 % increase in sales from the third quarter of 2020 was driven by increased sales of COVID - 19 diagnostic tests , led by QuickVue At - Home OTC COVID - 19 Test , and strong sales of Sofia® SARS and Lyra® PCR COVID - 19 tests . Currency exchange rate impact for the third quarter of 2021 was favorable by $ 1.0 million . Excluding COVID - 19 and influenza products , revenue for the core business increased 2 % to $ 93.3 million in the third quarter of 2021 , as compared to $ 91.4 million in the third quarter of 2020 . Rapid Immunoassay revenue increased by $ 41.7 million in the third quarter of 2021 to $ 378.7 million , driven primarily by continued demand for our Sofia SARS and QuickVue SARS antigen assays . Cardiometabolic Immunoassay revenue totaled $ 64.8 million in the third quarter of 2021 , equal to the third quarter of 2020. Molecular Diagnostic Solutions revenue decreased by $ 8.2 million to $ 54.8 million , due to a $ 14.3 million decline in sales of Lyra PCR assays for COVID - 19 diagnosis that was partially offset by incremental revenue from our Solana® SARS - CoV - 2 assay . Specialized Diagnostic Solutions revenue increased 2 % from the third quarter of 2020 to $ 11.4 million , driven by increased MicroVue ™ specialty products . " We delivered strong top - line growth in the third quarter of 2021 , meeting increased demand for our SARS category products due to the sudden increase in COVID - 19 cases associated with the Delta variant , ” said Douglas Bryant , President and CEO of Quidel . While we are pleased to see COVID - 19 cases trending down , we still see the need for symptomatic and asymptomatic testing and anticipate that a baseline level of demand will continue into early 2022 . Our expectations are bolstered by consumer , corporate and institutional purchasing and the 12 - month agreement to supply over $ 500 million in QuickVue At - Home OTC COVID - 19 Tests to the federal government . " Mr. Bryant added , " From a production capacity perspective , we continue to build toward our planned capacity goals for our QuickVue and Sofia diagnostic tests to support our institutional and government partnerships , and further promote rapid testing to minimize the spread of COVID - 19 within our communities . In that regard , I am particularly proud of our work with charitable and